drugset / Trial / NCT00099593

Immunization Against Tumor Cells in Sezary Syndrome

NCT00099593

Phase 2 Completed 17 enrolled University of Pittsburgh
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research is being done to look at the safety and value of a vaccine for a cancer found in the blood and skin known as Cutaneous T-cell lymphoma (CTCL) and Sezary Syndrome. In the laboratory, researches found that special white blood cells, called dendritic cells (DCs), are able to stimulate the immune system (groups of cells that protect the body from germs and diseases) in a way that helps your body fight cancer. Autologous (from your own body) DCs will be prepared (mixed together) in the laboratory with your cancer cell (Sezary cells) to allow your DCs to pick up parts of your Sezary cells to make the vaccine for you.

Timeline

Start
2004-09
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous dendritic cell vaccine Vaccine